TickerFacts.

Company research / ABBV

AbbVie Inc. (ABBV)

Build a valuation ↗↓ Download CSV

CIK 0001551152 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, AbbVie Inc. reported revenue of $61.16B. Revenue grew 8.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $64.39B.

Key ratios (year ended 2025-12-31)

70.2%
Gross margin (computed)
24.6%
Operating margin
6.9%
Net margin
8.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Headquarters locality: North Chicago · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$64.39B$61.16B$56.33B$54.32B$58.05B$56.20B$45.80B$33.27B$32.75B$28.22B$25.64B
Cost of Revenue$18.36B$18.20B$16.90B$20.41B$17.41B$17.45B$15.39B$7.44B$7.72B$7.04B$5.83B
Gross Profit (computed)$46.02B$42.96B$39.43B$33.90B$40.64B$38.75B$30.42B$25.83B$25.04B$21.17B$19.81B
R&D Expense$9.71B$9.10B$12.79B$7.67B$6.51B$6.92B$6.38B$6.41B$10.33B$5.01B$4.38B
Operating Income$16.87B$15.07B$9.14B$12.76B$18.12B$17.92B$11.36B$12.98B$6.38B$9.54B$9.34B
Net Income$6.31B$4.23B$4.28B$4.86B$11.84B$11.54B$4.62B$7.88B$5.69B$5.31B$5.95B
EPS (Diluted)n/a$2.36$2.39$2.72$6.63$6.45$2.72$5.28$3.66$3.30$3.63
Total Assets$135.12B$133.96B$135.16B$134.71B$138.81B$146.53B$150.56B$89.11B$59.35B$70.79B$66.10B
Long-Term Debtn/a$64.50B$66.84B$59.24B$63.13B$75.96B$84.95B$67.23Bn/an/an/a
Shareholders' Equity-$5.93B-$3.27B$3.33B$10.36B$17.25B$15.41B$13.08B-$8.17B-$8.45B$5.10B$4.64B
Cash & Equivalents$6.57B$5.23B$5.52B$12.81B$9.20B$9.75B$8.45B$39.92B$7.29B$9.30B$5.10B
Operating Cash Flow$19.51B$19.03B$18.81B$22.84B$24.94B$22.78B$17.59B$13.32B$13.43B$9.96B$7.04B
Capital Expenditures$1.30B$1.21B$974.00M$777.00M$695.00M$787.00M$798.00M$552.00M$638.00M$529.00M$479.00M
Free Cash Flow$18.21B$17.82B$17.83B$22.06B$24.25B$21.99B$16.79B$12.77B$12.79B$9.43B$6.56B
Share Repurchases$1.50B$980.00M$1.71B$1.97B$1.49B$934.00M$978.00M$629.00M$12.01B$1.41B$6.03B
Dividends Paid$11.98B$11.66B$11.03B$10.54B$10.04B$9.26B$7.72B$6.37B$5.58B$4.11B$3.72B
Dividends Per Sharen/a$6.65$6.29$5.99$5.71$5.31$4.84$4.39$3.95$2.63$2.35
Weighted Average Diluted Sharesn/a1.77B1.77B1.77B1.78B1.78B1.67B1.48B1.55B1.60B1.63B
EPS (Basic)n/a$2.37$2.40$2.73$6.65$6.48$2.73$5.30$3.67$3.31$3.65

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView